- Home
- SLI vs CSTL Comparison
SLI vs CSTL Comparison
Compare SLI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLI
- CSTL
- Stock Information
- Founded
- SLI 1998
- CSTL 2007
- Country
- SLI Canada
- CSTL United States
- Employees
- SLI N/A
- CSTL N/A
- Industry
- SLI Major Chemicals
- CSTL Medical Specialities
- Sector
- SLI Industrials
- CSTL Health Care
- Exchange
- SLI Nasdaq
- CSTL Nasdaq
- Market Cap
- SLI 595.8M
- CSTL 697.9M
- IPO Year
- SLI N/A
- CSTL 2019
- Fundamental
- Price
- SLI $2.92
- CSTL $21.82
- Analyst Decision
- SLI Buy
- CSTL Strong Buy
- Analyst Count
- SLI 2
- CSTL 6
- Target Price
- SLI $3.58
- CSTL $37.67
- AVG Volume (30 Days)
- SLI 1.4M
- CSTL 449.5K
- Earning Date
- SLI 11-11-2025
- CSTL 11-03-2025
- Dividend Yield
- SLI N/A
- CSTL N/A
- EPS Growth
- SLI N/A
- CSTL N/A
- EPS
- SLI N/A
- CSTL N/A
- Revenue
- SLI N/A
- CSTL $346,269,000.00
- Revenue This Year
- SLI N/A
- CSTL N/A
- Revenue Next Year
- SLI N/A
- CSTL N/A
- P/E Ratio
- SLI N/A
- CSTL N/A
- Revenue Growth
- SLI N/A
- CSTL 20.40
- 52 Week Low
- SLI $1.08
- CSTL $14.59
- 52 Week High
- SLI $3.13
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- SLI 53.66
- CSTL 51.42
- Support Level
- SLI $2.77
- CSTL $21.28
- Resistance Level
- SLI $3.11
- CSTL $24.74
- Average True Range (ATR)
- SLI 0.16
- CSTL 1.09
- MACD
- SLI -0.01
- CSTL -0.34
- Stochastic Oscillator
- SLI 44.87
- CSTL 15.61
About SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.